Innovative Nanobody-Fc Fusion Targeting FCGR2B and Immunoglobulin G for Immunological Disorders
VHH-P300 is an advanced humanized nanobody-based therapeutic candidate specifically engineered to target Fc gamma receptor IIb (FCGR2B) as well as Immunoglobulin G (IgG). Utilizing a unique Fc fusion protein structure, VHH-P300 is currently under biological testing and demonstrates significant potential for the treatment of immunological disorders. By precisely engaging both FCGR2B and Immunoglobulin G, VHH-P300 aims to modulate immune system activity, providing a targeted approach to restore immune homeostasis in various pathologies where immune dysregulation is central.
| Candidate | VHH-P300 |
| Target | Fc gamma receptor IIb (FCGR2B) Immunoglobulin G |
| Modality | humanized bispecific VHH |
| Indication | Immunological Disorders |
Licensing Opportunity
VHH-P300 is available for global licensing and partnering opportunities. We welcome inquiries from organizations seeking to collaborate on the further development or commercialization of this promising asset in immunological disorder therapeutics.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P300 |
Modality
VHH-P300 features a single domain nanobody fused to a modified human IgG1 Fc domain, constructed for high specificity and enhanced manufacturability. The nanobody’s small molecular weight and single-domain structure translate into superior tissue penetration and robust stability compared to conventional antibodies. The Fc fusion further augments in vivo half-life and effector modulation potential. Manufactured in human embryonic kidney cells, this format enables advantageous pharmacokinetic properties and scalable production. The molecular design of VHH-P300 offers unique benefits in treating immunological disorders, such as improved target engagement, reduced immunogenicity, and the flexibility required for next-generation biotherapeutic engineering.
Target
FCGR2B and Immunoglobulin G are key molecular components involved in the regulation of the immune system. FCGR2B is an inhibitory receptor primarily expressed on B cells, macrophages, and dendritic cells. Immunoglobulin G, the most abundant antibody in circulation, plays a critical role in immune defense. Scientific literature recognizes the importance of FCGR2B and Immunoglobulin G in balancing immune activation and inhibition, which is particularly relevant in immunological disorders characterized by autoimmune dysregulation or pathological inflammation. Targeting FCGR2B and Immunoglobulin G allows VHH-P300 to precisely regulate immune responses, presenting a strategically attractive asset for the treatment and potential management of diverse immunological conditions.
Mechanism of Action
VHH-P300 exerts its effects by binding both FCGR2B and the Fc region of Immunoglobulin G. Through this dual targeting, the molecule modulates downstream immune signal transduction pathways associated with FCGR2B, reducing abnormal activation and promoting immunological balance. By engaging the Fc region of IgG, VHH-P300 can mediate selective interference with autoantibody-driven processes, relevant in many immunological disorders. This signal transduction modulation holds promise for broader applications due to the modularity of the nanobody platform, which can be adapted for antibody-drug conjugates, bispecific formats, and multivalent therapeutics addressing complex immunopathologies.
Immunological Disorders
Immunological disorders represent a heterogeneous class of diseases involving aberrant immune responses, including conditions such as autoimmune diseases, hypersensitivity reactions, and immunodeficiencies. Their global impact is substantial, reflected in significant patient morbidity and healthcare resource demands. Standard therapies encompass immunosuppressants, biologics targeting immune checkpoints, and immunomodulatory agents. However, many patients exhibit only partial responses or develop resistance and adverse effects, leaving substantial unmet medical needs for safer and more precise therapies. The innovative dual-targeting modality of VHH-P300 enables fine-tuned immune modulation with the aim of correcting pathogenic immune circuits while preserving protective immunity, providing promising therapeutic potential for a wide spectrum of patients suffering from immunological disorders.